Sharon Townson sold $140k of GLUE
Chief Scientific Officer at Monte Rosa Therapeutics, Inc.. 6,000 shares at an average of $23.31, traded Jul 6, 2026, filed Jul 7, 2026.
Score components
- +15RoleOfficer
- +11Trade size$140k at market
- 0Share of holdings soldSold 8.1% of holdings
- +15Cluster5 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-26-297558, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jul 6, 2026 | MOption exercise Common Stock10b5-1 | +6,000 | $6.14 | $37k | 73,845 | Jul 7, 2026 |
| Jul 6, 2026 | SOpen-market sale Common Stock10b5-1 | -5,600 | $23.25 | $130k | 68,245 | Jul 7, 2026 |
| Jul 6, 2026 | SOpen-market sale Common Stock10b5-1 | -400 | $24.13 | $9,652 | 67,845 | Jul 7, 2026 |
| Jul 6, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -6,000 | $0.00 | $0 | 197,290 | Jul 7, 2026 |
Related signals
Other insiders at Monte Rosa Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 15Weak | GLUEsell Monte Rosa Therapeutics, Inc. | Matthew Bowen Principal Accounting Officer | $137 13 shares | -0% | |
| 52Moderate | Monte Rosa Therapeutics, Inc. | Markus Warmuth President & CEO | $220k 9,500 shares | -2% | |
| 10Weak | Monte Rosa Therapeutics, Inc. | Jennifer Champoux Chief Operating Officer | $102k 4,351 shares | -7% | |
| 6Weak | Monte Rosa Therapeutics, Inc. | Filip Janku Chief Medical Officer | $132k 5,407 shares | -8% | |
| 6Weak | Monte Rosa Therapeutics, Inc. | Filip Janku Chief Medical Officer | $138k 6,000 shares | -9% | |
| 48Moderate | Monte Rosa Therapeutics, Inc. | Anthony M. Manning director | $231k 10,000 shares | -100% | |
| 6Weak | Monte Rosa Therapeutics, Inc. | Jennifer Champoux Chief Operating Officer | $44k 2,175 shares | -3% | |
| 38Weak | Monte Rosa Therapeutics, Inc. | Filip Janku Chief Medical Officer | $882k 41,845 shares | -58% | |
| 2Weak | Monte Rosa Therapeutics, Inc. | Sharon Townson Chief Scientific Officer | $60k 3,000 shares | -4% | |
| 6Weak | Monte Rosa Therapeutics, Inc. | Jennifer Champoux Chief Operating Officer | $41k 2,176 shares | -3% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.